With mishaps in clinical trials coming to light, many see them in negative light. However, the brouhaha created around clinical trials is not true, said Dr Srinu Babu Gedela, founding director, OMICS Group Inc, USA.
Speaking at the 2nd International Conference of Pharmaceutical Regulatory Affairs (Pha-rma-2012) here on Friday, he said: “Clinical trials are hyped and often, seen in negative light. But, it is also important to test a drug which will have long-term benefits for the industry,” he said.
Stating an example of how WHO declared that India a Polio-endemic nation, Mr Srinu Babu expla-ined that it took 40 long years for the government and the civil society to eliminate the disease.
“Long-term implementation always benefits the society,” he added.
On drug pricing, Loks-atta president and MLA Dr Jayaprakash Narayan said the pharma sector has to bring in a mechanism blending efficacy, safety and cost effectiveness.
“Intervention and regulatory action of the pharma industry is required to bring about a pricing strategy where quality is not compromised to price.
The country’s pharma sector has touched $17 billion till October this year while the industry is growing at 17 per cent annually.